Chemotherapy of trypanosomiasis: the use of guanylhydrazone compounds in the treatment of experimental murine trypanosomiasis.
The efficacy of 1,3,5-triacetylbenzene tris(guanylhydrazone) trihydrochloride i.e. [(TBG)] in the treatment of early and late stage infections of Trypanosoma brucei in mice was investigated. Successful treatment on day 3 after infection could be achieved by doses of 2 X 2.5 mg kg-1. If treatment was delayed to 21 days after infection then the mice had to be given either suramin (1 X 20 mg kg-1) or difluoromethyl-ornithine (DFMO) 2% solution for 14 days in addition to either 15 mg kg-1 (TBG) daily for 4 days or 10 mg kg-1 twice daily for 4 days to obtain permanent cures. Other guanylhydrazone compounds were investigated for the treatment of chronic T. brucei infections and, at the limited dose levels used, failed to give any permanent cures. The use of (TBG) in the treatment of early and late stage infections of T. congolense and T. evansi indicated that treatment on day 3 after infection could be successful but on day 21 after infection the results were disappointing.
D000818:Animals; D004359:Drug Therapy, Combination; D000518:Eflornithine / Q000627:therapeutic use; D005260:Female; D051379:Mice; D008935:Mitoguazone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013498:Suramin / Q000627:therapeutic use; D014344:Trypanocidal Agents / Q000627:therapeutic use*; D014345:Trypanosoma / Q000187:drug effects; D014346:Trypanosoma brucei brucei / Q000187:drug effects; D014348:Trypanosoma congolense / Q000187:drug effects; D014353:Trypanosomiasis, African / Q000188:drug therapy*
D014344:Trypanocidal Agents; D013498:Suramin; C040056:1,3,5-triacetylbenzene tris(guanylhydrazone); D008935:Mitoguazone; D000518:Eflornithine